ABBV vs GILD
By Alex · Tickerpine
AbbVie Inc. vs Gilead Sciences, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | GILD |
|---|---|---|
| Price | $248.76 | $135.87 |
| Market cap | $439.59B | $168.47B |
| P/E ratio | 70.5 | — |
| ROE | — | -20.68% |
| Profit margin | 9.80% | -10.64% |
| Revenue growth | 10.20% | 10.20% |
| Dividend yield | 2.77% | 2.42% |
| Beta | 0.28 | 0.34 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs GILD in plain English
- ABBV is the bigger company — about 2.6× the market cap of GILD.
- GILD is growing revenue faster (10% vs 10%).
- ABBV has the higher dividend yield (2.77% vs 2.42%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
GILD return calculator
See what $1,000 in Gilead Sciences, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.